Psyence Group Inc. (PSYGF)
USD 0.3
(0.0%)
USD 0.3
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 | -97.92 Thousand CAD | -6.13% |
| 2023 | -92.26 Thousand CAD | -75.3% |
| 2022 | -52.63 Thousand CAD | -114.88% |
| 2021 | -24.49 Thousand CAD | 0.0% |
| 2020 | - CAD | 0.0% |
| 2019 | - CAD | 0.0% |
| 2018 | - CAD | 0.0% |
| 2017 | - CAD | 0.0% |
| 2016 | - CAD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 FY | -97.92 Thousand CAD | -6.13% |
| 2024 Q4 | -28.88 Thousand CAD | -27.81% |
| 2024 Q3 | -22.59 Thousand CAD | 3.32% |
| 2024 Q2 | -23.37 Thousand CAD | -1.28% |
| 2024 Q1 | -23.07 Thousand CAD | -316.5% |
| 2023 Q3 | -26.85 Thousand CAD | -25.18% |
| 2023 Q4 | -5541.00 CAD | 79.37% |
| 2023 Q1 | -12.42 Thousand CAD | 18.08% |
| 2023 FY | -92.26 Thousand CAD | -75.3% |
| 2023 Q2 | -21.45 Thousand CAD | -72.74% |
| 2022 FY | -52.63 Thousand CAD | -114.88% |
| 2022 Q3 | -14.61 Thousand CAD | 1.86% |
| 2022 Q2 | -14.89 Thousand CAD | -87.0% |
| 2022 Q1 | -7964.00 CAD | 0.0% |
| 2022 Q4 | -15.16 Thousand CAD | -3.74% |
| 2021 FY | -24.49 Thousand CAD | 0.0% |
| 2021 Q4 | - CAD | 0.0% |
| 2021 Q2 | - CAD | 0.0% |
| 2021 Q3 | - CAD | 0.0% |
| 2021 Q1 | - CAD | 0.0% |
| 2020 FY | - CAD | 0.0% |
| 2019 FY | - CAD | 0.0% |
| 2018 FY | - CAD | 0.0% |
| 2017 FY | - CAD | 0.0% |
| 2016 FY | - CAD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| AstraZeneca PLC | 34.69 Billion USD | 100.0% |
| Bristol-Myers Squibb Company PFD CONV 2 | 34.31 Billion USD | 100.0% |
| CSPC Pharmaceutical Group Limited | 30.13 Billion USD | 100.0% |
| Clarus Therapeutics Holdings, Inc. | 11.23 Million USD | 100.871% |
| Novartis AG | 34.18 Billion USD | 100.0% |
| PT Kalbe Farma Tbk. | 743.47 Million USD | 100.013% |